We conducted a 78-week trial comparing alirocumab (150 mg every 2 weeks) with placebo in 2341 patients at high risk for cardiovascular events who were receiving treatment with statins at the maximum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results